Related Experiment Video
Updated: Apr 9, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Intraprocedural thrombotic events: What's the real cost?
Michael J Lipinski1, Lowell F Satler1
1Section of Interventional Cardiology, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, District of Columbia.
Abstract:
Intraprocedural thrombotic events (IPTE) during PCI occur in 4% of patients with NSTEACS and 12% of STEACS. IPTE increases hospital cost by $3,592. With an incidence of 4%, additional therapy to completely prevent IPTE in 100 patients would need to cost $144 to make it cost neutral. Further studies are necessary to determine cost-benefit of therapies to prevent IPTE such as cangrelor or newer P2Y12 inhibitors with more rapid onset.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

